Intrexon | XON - Net Income

Stock Price
3.34
Daily Change
-0.22 -6.06%
Monthly
-22.26%
Yearly
78.34%
Q1 Forecast
3.67

Intrexon reported $-20.32M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Agenus USD -25.27M 20.59M Mar/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Anika Therapeutics USD -4.87M 16.99M Mar/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Incyte USD 299.28M 124.89M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Thermo Fisher Scientific USD 1.96B 348M Dec/2025
Veracyte USD 41.15M 22.01M Dec/2025
Xencor USD -6.65M 626K Dec/2025